Kornitzer Capital Management Inc. KS Acquires 28,050 Shares of ICON Public Limited (NASDAQ:ICLR)

Kornitzer Capital Management Inc. KS grew its holdings in ICON Public Limited (NASDAQ:ICLR) by 40.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 97,102 shares of the medical research company’s stock after acquiring an additional 28,050 shares during the quarter. Kornitzer Capital Management Inc. KS owned 0.12% of ICON Public worth $20,363,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. Sierra Ocean LLC bought a new stake in ICON Public during the 4th quarter worth approximately $29,000. Park Place Capital Corp increased its position in shares of ICON Public by 281.4% during the fourth quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock worth $47,000 after acquiring an additional 166 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after acquiring an additional 169 shares during the period. Whittier Trust Co. of Nevada Inc. lifted its position in ICON Public by 23.1% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock valued at $147,000 after acquiring an additional 96 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its stake in ICON Public by 33.9% in the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after purchasing an additional 151 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on ICLR. TD Cowen cut their price target on ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a report on Friday, October 25th. William Blair restated an “outperform” rating on shares of ICON Public in a research note on Tuesday, January 14th. Leerink Partners reaffirmed an “outperform” rating and set a $255.00 price target (down from $270.00) on shares of ICON Public in a research note on Tuesday, November 19th. Royal Bank of Canada reissued an “outperform” rating and issued a $263.00 price objective on shares of ICON Public in a research report on Wednesday, January 15th. Finally, The Goldman Sachs Group decreased their target price on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $283.92.

ICON Public Stock Performance

Shares of NASDAQ ICLR opened at $186.21 on Tuesday. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $15.36 billion, a P/E ratio of 20.76, a P/E/G ratio of 1.78 and a beta of 1.19. ICON Public Limited has a 12 month low of $181.51 and a 12 month high of $347.72. The stock has a 50 day moving average of $204.18 and a 200-day moving average of $247.73.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.